Abstract
Programmed death-1 (PD-1) occurs widely in a variety of human immune cells and tumor cells. When PD-1 is combined with programmed death-1 ligand (PD-L1), T-lymphocyte will be exhausted eventually resulting in tumor immune escape. Experiments in vitro and in vivo have demonstrated that inhibiting the binding of PD-1 with PD-L1, and blocking downstream signaling pathways can enhance endogenous anti-neoplastic immune effects. The expression of PD-1/PD-L1 is related to the clinical stage and prognosis of esophageal cancer patients, which may become the clinical biomarkers, serving as a new target for cancer immunotherapy. This paper reviews the relationship between PD-1/PD-L1 and esophageal cancer as well as the related treatment progress. Key words: Esophageal neoplasms; Programmed death-1; Programmed death-1 ligand; Tumor immunity
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
